CN109182162B - 一株具有抗氧化能力的植物乳杆菌及应用 - Google Patents
一株具有抗氧化能力的植物乳杆菌及应用 Download PDFInfo
- Publication number
- CN109182162B CN109182162B CN201810941395.3A CN201810941395A CN109182162B CN 109182162 B CN109182162 B CN 109182162B CN 201810941395 A CN201810941395 A CN 201810941395A CN 109182162 B CN109182162 B CN 109182162B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- strain
- lactobacillus
- strains
- lactic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 31
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 26
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 26
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 26
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 235000013402 health food Nutrition 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000002537 cosmetic Substances 0.000 claims description 3
- 235000021001 fermented dairy product Nutrition 0.000 claims description 3
- 235000021107 fermented food Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 22
- 241000186660 Lactobacillus Species 0.000 abstract description 18
- 229940039696 lactobacillus Drugs 0.000 abstract description 18
- 239000006041 probiotic Substances 0.000 abstract description 17
- 235000018291 probiotics Nutrition 0.000 abstract description 17
- 238000012360 testing method Methods 0.000 abstract description 16
- 230000003647 oxidation Effects 0.000 abstract description 15
- 238000007254 oxidation reaction Methods 0.000 abstract description 15
- 230000000529 probiotic effect Effects 0.000 abstract description 15
- 230000032683 aging Effects 0.000 abstract description 13
- 238000000338 in vitro Methods 0.000 abstract description 8
- 230000000968 intestinal effect Effects 0.000 abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 6
- 108090000790 Enzymes Proteins 0.000 abstract description 6
- 230000002209 hydrophobic effect Effects 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 6
- 239000004460 silage Substances 0.000 abstract description 6
- 235000013618 yogurt Nutrition 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 59
- 241000894006 Bacteria Species 0.000 description 47
- 239000004310 lactic acid Substances 0.000 description 29
- 235000014655 lactic acid Nutrition 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 235000006708 antioxidants Nutrition 0.000 description 17
- 230000001580 bacterial effect Effects 0.000 description 16
- 229920001817 Agar Polymers 0.000 description 15
- 239000008272 agar Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000000284 extract Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 210000005013 brain tissue Anatomy 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000008055 phosphate buffer solution Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000002000 scavenging effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 230000003064 anti-oxidating effect Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 239000003833 bile salt Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241000570445 Elymus nutans Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000006153 eosin methylene blue Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- CDUFCUKTJFSWPL-UHFFFAOYSA-L manganese(II) sulfate tetrahydrate Chemical compound O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O CDUFCUKTJFSWPL-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AVPCPPOOQICIRJ-UHFFFAOYSA-L sodium glycerol 2-phosphate Chemical compound [Na+].[Na+].OCC(CO)OP([O-])([O-])=O AVPCPPOOQICIRJ-UHFFFAOYSA-L 0.000 description 1
- 229960002901 sodium glycerophosphate Drugs 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- -1 superoxide radicals Chemical class 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000020255 yak milk Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一株具有抗氧化能力的植物乳杆菌,保藏号为CGMCC15780,本发明还包括该菌株的应用。所述植物乳杆菌从青藏高原传统发酵牦牛酸奶和青贮饲料中筛选具有高抗氧化能力的乳酸菌菌株,经过体内体外试验证明,其具有较好的抗氧化能力,能有效促进体内抗氧化酶活性的增加。该菌株较好的疏水能力增加了其黏附到肠道壁并发挥益生作用的机会,无毒副作用,可作为保健食品或药品提高机体免疫力、抗衰老、美容以及调节肠道菌群等。
Description
技术领域
本发明涉及生物技术领域,尤其涉及功能性乳酸菌开发与应用领域,特别是一株具有高抗氧化功能的植物乳杆菌,本发明还包括该植物乳杆菌的应用。
背景技术
氧化作用是机体的必要代谢过程,但过度的氧化作用会引起生物大分子的损伤。氧化应激是导致机体衰老和衰老相关疾病的根本原因。
自由基具有强烈的氧化作用,可以引发脂质过氧化反应造成细胞膜受损,进而使细胞死亡。当人体有过量自由基产生时,自由基会与人体细胞内的蛋白质、核酸等生物大分子结合,并破坏它们的结构和功能。自由基对人的具体危害如下:(1)削弱细胞的抵抗力,使身体易受细菌和病菌感染;(2)产生破坏细胞的化学物质,形成致癌物质;(3)阻碍细胞的正常发展,干扰其复原功能,使细胞更新率低于死亡率;(4)破坏体内的遗传基因阻止,扰乱细胞的运作及再生功能,造成基因突变,演变成癌症;(5)破坏细胞内的线粒体,造成氧化性疲劳;(6)破坏细胞膜,干扰细胞的新陈代谢,使细胞膜丧失保护细胞的功能;(8)破坏蛋白质,破坏体内的酶,导致炎症和衰老;(9)破坏脂肪,使脂质过氧化,导致动脉粥样硬化,发生心脑血管疾病;(10)破坏碳水化合物,使透明质酸降解,导致关节炎。从以上所述十点可知,自由基是人体健康的杀手。
益生菌在自然界中分布广泛,是一种可以通过改善肠道微生物的平衡来对宿主产生有益影响的微生物。目前应用最为广泛的益生菌是乳杆菌和双歧杆菌等,它们是人体肠道内重要的生理菌,对机体有多种生理作用。益生菌可以调整肠道菌群平衡,提高蛋白质和维生素的代谢,产生抗菌素来抑制有害菌群生长,抗肿瘤,增强免疫力,降低血清胆固醇,抗氧化延缓衰老等。因此,将益生菌应用于功能性食品开发具有重要意义。而具有抗氧化功能的 乳酸菌可以通过清除人体内过多的自由基来使人体维持正常状态,此外,乳酸菌产生的非酶物质能够通过抑制有害菌的生长来减少毒性物质的产生,从而发挥抗衰老作用。
青藏高原独特的极端环境高海拔、低压、强紫外线、低温等会造成有机体内的氧化胁迫。Dosek等(2007)报道,长期暴露在高海拔的环境下伴随大气中氧浓度减少会造成氧化胁迫,提高机体内活性氧浓度,造成细胞中蛋白质、DNA等大分子物质的破坏。同样,基于生物对环境的适应性原理,长期生存在该环境下的生物体为了适应这种氧化胁迫有可能产生具有高抗氧化能力的特殊遗传特性和机制。因此,在青藏高原极端环境下更有可能筛选出具有高抗氧化能力的特殊功能乳酸菌,且具有更独特的开发和应用价值。
由此,具有高抗氧化能力益生菌具有较大的应用价值,对维持人体健康具有十分重要的意义。
发明内容
本发明的目的在于提供一种高原植物乳杆菌,具有高抗氧化活性,能够有效清除机体内自由基。
为实现上述目的,本发明采用下述技术方案:
一株具有抗氧化能力的植物乳杆菌(Lactobacillus plantarum),其保藏编号为CGMCC15780。
所述的一株具有抗氧化能力的植物乳杆菌的筛选方法,从青藏高原传统牦牛酸奶和天然垂穗披碱草青贮饲料中筛选具有高抗氧化能的乳酸菌菌株。
具体筛选工艺步骤如下:
(1)本发明从青藏高原传统牦牛酸奶和天然垂穗披碱草青贮饲料中分离、筛选和鉴定的34株乳酸菌,通过将它们与1株购自与中国普通微生物菌种保藏管理中心的标准菌Lactobacillus rhamnosus GG做对比,筛选出一种具有高抗氧化能力、延缓衰老且维持基本益生特性,能在体内发挥抗氧化特殊益生功能的乳酸菌菌株。
(2)青藏高原传统发酵牦牛酸奶中的微生物通过MRS、M17、KFS和SL四种不同的培养基培养,挑选特征菌株并纯化,得到纯分离的菌株。
(3)结合过氧化氢阴性、革兰氏染色阳性、菌体形态以及镜检分离挑选似乳酸菌菌株,进行16S rDNA 测序,NCBI中进行Blast比对,鉴定并保存34株乳酸菌菌株。
(4)测定(3)中已鉴定的乳酸菌菌体的DPPH清除能力进行初筛,共筛选出11株清除能力较好的菌株。
(5)测定并研究(4)中筛选出的11株菌株对DPPH、OH和O2-自由基的清除能力;
(6)测定具高抗氧化活性乳酸菌抗氧化酶活性,包括总抗氧化能力 (T-AOC)、SOD和GSH-PX活性。
(7)通过体外益生特性试验评价乳酸菌的体外益生特性,进一步筛选出高抗氧化活性益生乳酸菌。
(8)通过动物实验,检测对比衰老模型小鼠体内的抗氧化指标,检验筛选出的具高抗氧化活性乳酸菌的摄入对衰老模型小鼠是否具有明显的抗氧化益生作用。
(9)通过步骤(1)~(8)得到具有高抗氧化活性和体内外益生特性的植物乳杆菌24-7。
(10)将菌株24-7的16S rRNA基因序列在Genbank进行注册,获得Genbank数据库菌株24-7的序列号:MF179626。
本发明所述具有高抗氧化能力的植物乳杆菌24-7已于2018 年5月21 日保藏在中国微生物菌种保藏管理委员会普通微生物中心,地址为北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,保藏编号为CGMCC15780。
所述的具有高抗氧化能力的植物乳杆菌在制备发酵乳制品及其他发酵食品中的应用。
所述的具有高抗氧化能力的植物乳杆菌在制备保健食品、化妆品和药品中的应用。
本发明提供的上述具有高抗氧化活性的植物乳杆菌具有较强的超氧化物歧化酶和谷胱甘肽气化酶活性,在胆盐耐受能力、抑菌能力、疏水能力以及模拟胃肠道的体外试验中都表现较好的益生特性。能够应用在制备发酵乳制品及保健品和药品中。
本发明提供的上述具有高抗氧化活性的植物乳杆菌能够有效减少衰老老鼠中脑组织的损伤,提高老鼠肝脏和血清中谷胱甘肽过氧化物酶(GSH-Px)的活性,并且还可以提高老鼠血清和脑中总超氧化物歧化酶(T-SOD)的活性,降低血清中丙二醛(MDA)的含量,能够广泛应用在发酵食品、保健、化妆品和药品中,具有抗氧化和清除自由基的能力,可提高机体免疫力。
附图说明
图1为本发明实施例1中高DPPH清除能力乳酸菌与参考菌株的对比;
图2为本发明实施例1中乳酸菌及相应的参考菌无细胞提取液中T-AOC活性;
图3为本发明实施例1中乳酸菌及相应的参考菌无细胞提取液对HO•自由基的清除能力;
图4为本发明实施例1中乳酸菌及相应的参考菌无细胞提取液中O2 -清除能力;
图5为本发明实施例1中乳酸菌及相应的参考菌无细胞提取液中T-SOD活性;
图6为本发明实施例1中乳酸菌及相应的参考菌无细胞提取液中GSH-Px活性。
具体实施方式
以下结合具体实施例,并参照附图,对本发明进一步详细说明。
相关培养基配方及缓冲液配方
乳酸细菌培养基(MRS):蛋白胨10 g,牛肉膏10 g,酵母提取物5 g,柠檬酸氢二铵2g,葡萄糖20 g,吐温-80 1 mL,乙酸钠5 g,磷酸氢二钾2 g,硫酸镁0.58 g,硫酸锰0.25 g,琼脂15 g,蒸馏水1000 mL,pH 6.2-6.6。制法:将除琼脂外所有成分加入水中加热溶解,调pH 6.2~6.4,加入琼脂,121℃灭菌15 min,趁热倒平板。
M17培养基:精确称取植质蛋白胨5.0 g,酵母提取物5.0 g,聚蛋白胨5.0 g,抗坏血酸0.5 g,牛肉浸膏2.5 g,β-甘油磷酸二钠19 g,量取1.0 mol/L MgSO4•7H2O 1.0 mL,蒸馏水1000 mL,琼脂15 g。制法:将除琼脂外所有成分加入水中加热溶解,调 pH 7.0,加入琼脂,121℃灭菌15 min,趁热倒平板。
SL培养基:称取酪蛋白水解物 10 g,酵母提取物 5 g,柠檬酸氢二铵 2 g,乙酸钠25 g,七水硫酸镁0.58 g,琼脂 15 g,葡萄糖 20 g,吐温80 1.0 mL,磷酸氢二钾 6 g,七水硫酸亚铁 0.03 g,四水硫酸锰 0.15 g,蒸馏水1000 mL。制法:将除琼脂外所有成分加入水中加热溶解,调 pH 5.4,加入已加热溶解的琼脂,混合均匀,边搅拌边煮沸5 min,冷却到50℃,倒平板。
KFS链球菌选择性培养基:月示蛋白胨10 g,酵母粉10 g,甘油磷酸钠10 g,氯化钠5 g,麦芽糖20 g,乳糖1 g,叠氮钠0.4 g,琼脂13 g,溴甲酚紫0.015 g,调节pH 7.2。制法:将除琼脂外所有成分加入水中加热溶解,调 pH 7.2,加入琼脂,121℃灭菌15 min,冷却至50-60℃时,加入无菌1%TTC溶液10 mL,混匀,趁热倒平板。
营养培养基(NB):蛋白胨10 g,牛肉膏3 g,氯化钠5 g,蒸馏水1000 mL,pH 7.0。制法:将上述成分混合,溶解后调pH,121℃灭菌15min,冷却备用。制备营养培养基平板时,加入0.8%的琼脂。
脑心浸液肉汤(BHI):蛋白胨10 g,脱水小牛脑浸粉12.5 g,脱水牛心浸粉5 g,氯化钠5 g,葡萄糖2 g,磷酸氢二钠2.5 g,蒸馏水1000 mL,pH 7.4。制法:将上述成分混合,溶解后调pH,121℃灭菌15min,冷却备用。制备培养基平板时,加入0.8%的琼脂。
双歧杆菌培养基(BS)、伊红美蓝琼脂(EMB)培养基、乳杆菌(LBS)培养基均购自青岛高科园海博生物技术有限公司。
磷酸缓冲液(Phosphate buffer solution,PBS ): 磷酸二氢钾0.27 g、磷酸氢二钠1.42 g、氯化钠8 g、氯化钾0.2 g。加去离子水800 mL充分搅拌溶解,然后加入稀盐酸调pH到7.4,最后定容到1 L。
试验中采用的参考菌株
标准菌:Lactobacillus rhamnosus (LGG; ATCC53103),购自中国普通微生物菌种保藏管理中心(CGMCC)
实施例1:从青藏高原传统发酵牦牛酸奶和青贮饲料中分离并鉴定乳酸菌
一、样品来源
来源于我国甘肃省天祝藏族自治县传统发酵牦牛乳制品和青贮饲料。
二、从传统牦牛乳制品和青贮饲料中分离得到乳酸菌
取1 mL发酵牦牛乳制品按1:10比例,用灭菌生理盐水稀释,此为10-1稀释度。然后吸取1 mL上述稀释液,再10倍稀释,为10-2稀释度,以此类推。选取10-5、10-6、10-7三个稀释度,分别吸取100 μL稀释液分别均匀地涂布于MRS、M17、KFS和SL(调pH5.4)平板培养基上,接种的4种培养基依次分别在37℃、42℃、42℃和37℃厌氧恒温培养48小时,挑取特征菌落,并进一步纯化,得到纯分离的乳酸菌菌株。
三、对菌株进行鉴定
(1)革兰氏染色、过氧化氢酶实验
革兰氏染色:挑取平板上的纯菌落进行涂片、固定、结晶紫初染、碘液媒染、酒精脱色、番红复染、干燥、油镜镜检。蓝紫色为革兰氏阳性菌,红色为革兰氏阴性菌。
过氧化氢酶实验:将待测菌在空气中暴露30 min,用滴管吸取3% (体积分数)过氧化氢滴于平板表面所生长的菌落,2-3分钟后观察有气泡产生的为阳性,无为阴性。
该菌株革兰氏染色为阳性,过氧化氢实验为阴性,可初步视为乳酸菌。
(2)16SrRNA鉴定
纯化后的乳酸菌在MRS培养基中培养8 h后,10000rpm/min 离心3-5min收集菌体,按照试剂盒使用方法提取DNA。然后进行PCR扩增,在细菌的通用引物27F和1492R(Monis et al, 2005)的扩增下,进行16SrRNA的扩增。扩增条件:95℃ 5 min;95℃ 30s,55℃ 30s,72℃ 1 min 30s;72℃ 5 min,30次循环。PCR 产物送上海美吉生测序公司进行序列分析。将测得乳酸菌菌株16S rRNA 基因序列用BLAST(http://wwwncbi.nlm.nih.gov/blast/)在GenBank中搜索,与待测菌株同源性值大于98%,则可认为他们属于同一个种。可鉴定的乳酸菌共34株,全部用于高抗氧化能力乳酸菌的筛选。
实施例2:高抗氧化能力乳酸菌的筛选
一、乳酸菌完整细胞和无细胞提取物和发酵上清液的制备
细胞菌液的制备:将实验室-80℃保存的菌液接入已灭菌的MRS培养基中37℃培养过夜,连续传代3次。培养液经12,000 g 离心收集菌体,PBS洗涤3次,重悬于PBS,调整菌数。
无细胞提取液的制备:将菌液在37℃过夜活化两次,8000 g,10 min,4 ℃,离心收集菌体,PBS洗涤3次,重悬于PBS,调整菌数1×109 CFU/mL或1×1010 CFU/mL。冰浴超声破碎细胞,5 s,5 s,30 min,360 W。8000 g,10 min,4 ℃,收集上清液为无细胞提取物。
发酵上清液的制备:将活化好的乳酸菌接种于MRS液体培养基中,37℃培养24h,培养液经8000g,10min,4℃离心后上清液即为发酵上清液(FS)。
二、初筛
在灭菌的MRS液体培养基中分别添加H2O2溶液,使培养基中的起始H2O2浓度分别为0、1.0、2.0、3.0 mmol/L。将菌体浓度为1×108 CFU/mL的乳酸菌菌液按1%的接种量接种到含不同H2O2浓度的液体培养基中,置于37℃恒温培养箱中培养,8 h后用分光光度计测定在不同H2O2浓度下生长的乳酸菌菌液600 nm下的的OD值。
试验中筛选出11株高DPPH清除能力的乳酸菌。
三、复筛
将初筛中的11株高DPPH清除能力乳酸菌全部用于复筛。
(1)DPPH自由基清除能力
称取0.008 g DPPH溶于无水乙醇,定容至100 mL,配制成0.2 mmol/L DPPH。吸取1mL菌液(1×108 CFU/mL)加入2mL 0.2 mmol/L的 DPPH无水乙醇溶液,室温下(20~25 ℃)避光反应30 min,8000 g,4 ℃,离心10 min,取上清液,517 nm处测定上清液吸光度,去离子水调零(Shengyu Li,2000)。
DPPH清除率(%)=[1-(A i -A j )/A c ]×100
A i :1 mL DPPH+1 mL样品;A j :1 mL乙醇+1 mL样品;A c :1 mL DPPH+1 mL PBS。
(2)超氧阴离子(O2 -)清除能力的测定
本实验采用Liu等(2010a)的方法并略做修改。混合反应液包括:2.8 mL Tris-HCl(0.05 M,pH 8.2),0.1 mL 邻苯三酚(0.05 M),0.1 mL无细胞提取物。将混合反应液混匀,25℃,黑暗中反应4 min。反应结束后,添加1 mL 8 M HCl终止反应,在320 nm下检测吸光度。
超氧阴离子清除能力(%)=[1-A1/A0]×100%
A0为没有添加样品的空白对照,A1为添加样品的吸光度(Liu et al., 2010)。
(3)清除羟自由基(HO•)的能力
吸取0.5 mL无细胞提取物和1 mL O-菲啰啉(浓度0.1%),加入1 mL PBS,1 mL 2.5mmol/L FeSO4,1 mL 20 mmol/L H2O2。37 ℃恒温水浴反应1.5 h后,536 nm处测吸光值。利用以下公式计算超氧自由基的清除率:
清除率(%)=[(A2-A1)/(A0-A1)]×100%
式中:A0—不含样品和H2O2;A1—不含样品,含H2O2;A2—含样品和H2O2(Zhang etal.,2011)。
(4)总抗氧化能力(T-AOC)、超氧化物歧化酶(T-SOD)和谷胱甘肽过氧化物酶(GSH-Px)活性的测定
用试剂盒测定无细胞提取物和发酵上清液的T-AOC、T-SOD和GSH-Px活性,具体方法严格按照试剂盒说明书进行。
四、挑选综合抗氧化能力强的菌株
结合初筛和复筛中的各项抗氧化指标,挑选出1株综合抗氧化能力强的菌株,与ATCC53103标准菌株进行对比。图1、2、3、4、5、6表示筛选出的11株抗氧化能力表现较好乳酸菌的自由基清除能力,本发明植物乳杆菌24-7综合抗氧化能力表现较好,且高于参考菌株。为了进一步在这11株菌中挑选出能作为益生菌的优势菌株,以下试验进行体外益生特性研究,验证本发明菌株是否满足作为益生菌的基本条件。
实施例3:体外益生特性研究
一、发明菌株消化道模拟试验及疏水能力测定
(1)疏水能力
根据Mansona等(1992)的方法进行试验,将活化好的乳酸菌接种于液体MRS培养基,37℃培养16-18h,将菌液5000rpm/min离心,用0.1mol KNO3(pH6.2)洗涤两次后,用该溶液悬浮菌液,在600nm处测量其初始吸光度A0。再吸取菌悬液3ml,加入1ml二甲苯,室温预培养10min,涡流快速混合2min,室温静止放置15min使之分层,吸取下层水相,以缓冲液为空白对照,在600nm测量最终吸光度A并进行记录。
疏水能力(%)=(A0-A)/A0×100%
式中:A0和A分别是与二甲苯混匀前、后菌液在600nm下测量得到的吸光值。
(2)耐模拟胃肠液能力的测定
采用Charteris等(1998)的方法。具体步骤如下:
模拟胃液的配制:0.35 g胃蛋白酶溶于100 mL 0.2%的无菌生理盐水,用浓盐酸调节pH到3.0,过0.45 μm滤膜除菌。
模拟肠液的配制:0.1 g胰蛋白酶,1.8 g胆盐溶于无菌溶剂含1.1 g NaHCO3、0.2g NaCl及100 mL蒸馏水,用0.5 M 的NaOH调整pH到8.0。溶液过0.45 μm滤膜除菌。
将已活化3次的菌液按10%的接种量接种到模拟胃液(pH3)中,混匀,37℃厌氧培养,分别在0,3 h取样平板计数。在模拟胃液中培养3 h后,吸取1 mL培养液接种到9 mL模拟肠液(pH 8)中,37℃厌氧培养,分别在0,3,6,24 h取样计数。
计数用MRS培养平板,生理盐水梯度稀释,取样涂布,37℃厌氧培养48 h,计数30~300菌数的平皿。
存活率(%)=(log CFU N1/log CFU N0)×100%
N1代表经过模拟胃肠道培养后的乳酸菌数量;N0代表模拟胃肠道培养前的乳酸菌数量。
(3)耐胆盐能力
无菌MRS-THIO培养基(含0.2%巯基乙酸钠)中添加0.3%(W/V)的牛胆汁,然后接种1%的乳酸菌(已活化三次),对照组为不含牛胆汁的MRS-THIO培养液。水浴37℃培养,每两小时取样620 nm下测定吸光度,用不含乳酸菌的相对应的空白培养基调零。记录OD620nm变化0.3个单位的时间。推迟时间(LT)的计算为乳酸菌生长到OD620nm变化0.3个单位时所推迟的时间。LT越小耐胆盐能力越强(Walker和Gilliland,1993)。
表2表明24-7具有较好的消化道耐受能力以及疏水能力,能够在消化道环境中保持较高的存活率,且增加了黏附到肠道壁的机会,满足作为益生菌的基本条件。
实施例4:动物模型试验
一、发明菌株对衰老模型小鼠的益生作用
(1)小鼠喂养试验
40只雄性昆明小鼠,体重范围在20 g左右,于单独隔离的鼠笼中普通饲料喂养,自由采食和饮水,经7天的预试期后,空腹12 h,不限制饮水,称重。根据体重随机分为4组,每组10只,每个处理组饲喂基础日粮,试验期为6周。乳酸菌处理组每日分别灌胃乳酸菌活菌数(1010CFU/d),普通对照组和衰老模型组则每日灌胃等量的无菌生理盐水。衰老模型组、乳酸菌处理组每日接收腹腔注射5% D-半乳糖(500 mg/kg),普通对照组每日注射等量的生理盐水。试验分组及药剂分配见表3。
氧化衰老模型组试验鼠表现出明显的衰老体征(体重减少、毛色暗黄、行为缓慢、精神萎靡等)。最后一次灌胃和注射D-半乳糖后,停止进食8 h,不限制饮水。称重,摘眼球取血,室温放置,离心(4000 g,10 min)分离血清,-80℃保存备用。采血后劲椎脱臼处死,放置于冰上,分离肝、脑、心、肾、脾。用预冷的生理盐水冲洗表面血迹,医用纱布拭干,称重。按下式计算脏器比重:
称重后,将脑和肝脏组织用电动组织研磨器匀浆,并加入9倍体积预冷的生理盐水,混匀。将制备好的10%的匀浆液用低温离心机4 000 g离心10 min。取上清,-80℃保存,待测。
(2)小鼠血清、脑组织及肝脏组织中总抗氧化能力(T-AOC)
测定原理:许多抗氧化物质能使Fe3+还原成Fe2+,而Fe2+可与菲啉类物质结合构成稳定的络合物,比色法可检测其氧化能力的高低。具体方法根据南京建成试剂盒所配套的使用说明书的步骤进行。
(3)小鼠血清、脑组织及肝脏组织中谷胱甘肽过氧化物酶活力(GSH-Px)
每0.1 mL血清或每mg蛋白质,扣除非酶促反应作用的,使反应体系中GSH浓度降低1 μmol/L为一个酶活力单位,按照南京建成试剂盒说明书操作进行。
(4)小鼠血清和肝脏组织中丙二醛(MDA)含量
MDA测定采用硫代巴比妥酸法(TBA)测定,按照南京建成试剂盒说明书操作进行。
(5)小鼠血清、脑组织、肝脏组织中总超氧化物歧化酶活力(T-SOD)
每mL血清或每mg组织蛋白在1 mL反应液中SOD抑制率达50%时所对应的SOD量为一个SOD活力单位(U)。本试验采用黄嘌呤氧化酶法测定T-SOD。具体方法根据南京建成试剂盒完成。
见表4、5、6、7、8动物试验结果表明,24-7对小鼠脏器无毒副作用,可减少衰老老鼠脑组织的损伤。发明菌株24-7能显著提高小鼠肝脏、脑组织和血清的T-SOD、GSH-Px活性,降低小鼠血清中MDA的含量,其中肝脏的GSH-Px、T-AOC活性,脑组织和血清的T-SOD活性甚至能回到正常水平,具有体内抗氧化作用。
试验表明,本发明提供的菌株植物乳杆菌24-7体内体外试验都证明其具有较好的抗氧化能力,能有效促进体内抗氧化酶活性的增加。该菌株较好的疏水能力增加了其黏附到肠道壁并发挥益生作用的机会。该产品无毒副作用,可作为保健食品或药品提高机体免疫力、抗衰老、美容以及调节肠道菌群等。
SEQUENCE LISTING
<110> 甘肃普诺贝康生物科技有限责任公司
<120> 一株具有抗氧化能力的植物乳杆菌菌株24-7
<130> 4
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 1407
<212> RNA
<213> 植物乳杆菌(lactobacillus plantarum)
<400> 1
ccaccgactt tgggtgttac aaactctcat ggtgtgacgg gcggtgtgta caaggcccgg 60
gaacgtattc accgcggcat gctgatccgc gattactagc gattccgact tcatgtaggc 120
gagttgcagc ctacaatccg aactgagaat ggctttaaga gattagctta ctctcgcgag 180
ttcgcaactc gttgtaccat ccattgtagc acgtgtgtag cccaggtcat aaggggcatg 240
atgatttgac gtcatcccca ccttcctccg gtttgtcacc ggcagtctca ccagagtgcc 300
caacttaatg ctggcaactg ataataaggg ttgcgctcgt tgcgggactt aacccaacat 360
ctcacgacac gagctgacga caaccatgca ccacctgtat ccatgtcccc gaagggaacg 420
tctaatctct tagatttgca tagtatgtca agacctggta aggttcttcg cgtagcttcg 480
aattaaacca catgctccac cgcttgtgcg ggcccccgtc aattcctttg agtttcagcc 540
ttgcggccgt actccccagg cggaatgctt aatgcgttag ctgcagcact gaagggcgga 600
aaccctccaa cacttagcat tcatcgttta cggtatggac taccagggta tctaatcctg 660
tttgctaccc atactttcga gcctcagcgt cagttacaga ccagacagcc gccttcgcca 720
ctggtgttct tccatatatc tacgcatttc accgctacac atggagttcc actgtcctct 780
tctgcactca agtttcccag tttccgatgc acttcttcgg ttgagccgaa ggctttcaca 840
tcagacttaa aaaaccgcct gcgctcgctt tacgcccaat aaatccggac aacgcttgcc 900
acctacgtat taccgcggct gctggcacgt agttagccgt ggctttctgg ttaaataccg 960
tcaatacctg aacagttact ctcagatatg ttcttcttta acaacagagt tttacgagcc 1020
gaaacccttc ttcactcacg cggcgttgct ccatcagact ttcgtccatt gtggaagatt 1080
ccctactgct gcctcccgta ggagtttggg ccgtgtctca gtcccaatgt ggccgattac 1140
cctctcaggt cggctacgta tcattgccat ggtgagccgt taccccacca tctagctaat 1200
acgccgcggg accatccaaa agtgatagcc gaagccatct ttcaagctcg gaccatgcgg 1260
tccaagttgt tatgcggtat tagcatctgt ttccaggtgt tatcccccgc ttctgggcag 1320
gtttcccacg tgttactcac cagttcgcca ctcactcaaa tgtaaatcat gagcaagcac 1380
caatcaatac cagagttcgt tcgactg 1407
Claims (3)
1.一株具有抗氧化能力的植物乳杆菌(Lactobacillus plantarum),其特征在于,所述植物乳杆菌的保藏编号为CGMCC15780。
2.如权利要求1所述的一株具有抗氧化能力的植物乳杆菌在制备发酵乳制品及其他发酵食品中的应用。
3.如权利要求1所述的一株具有抗氧化能力的植物乳杆菌在制备保健食品、化妆品和药品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810941395.3A CN109182162B (zh) | 2018-08-17 | 2018-08-17 | 一株具有抗氧化能力的植物乳杆菌及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810941395.3A CN109182162B (zh) | 2018-08-17 | 2018-08-17 | 一株具有抗氧化能力的植物乳杆菌及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109182162A CN109182162A (zh) | 2019-01-11 |
CN109182162B true CN109182162B (zh) | 2021-10-26 |
Family
ID=64918217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810941395.3A Active CN109182162B (zh) | 2018-08-17 | 2018-08-17 | 一株具有抗氧化能力的植物乳杆菌及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109182162B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110272846A (zh) * | 2019-07-08 | 2019-09-24 | 江苏省农业科学院 | 具有abts自由基和ptio自由基清除活性的植物乳杆菌及其应用 |
CN110885767B (zh) * | 2019-09-24 | 2023-01-24 | 南昌大学 | 一株具有良好抗氧化活性的乳酸乳球菌霍氏亚种及其应用 |
CN110684697B (zh) * | 2019-11-13 | 2021-06-25 | 山东农业大学 | 一种具有抗氧化功能的发酵乳杆菌jx306及其用途 |
CN111235070B (zh) * | 2020-03-18 | 2022-03-08 | 河北农业大学 | 一株母乳婴儿源植物乳杆菌bf_15及其应用 |
CN112111430B (zh) * | 2020-09-27 | 2022-10-21 | 吉林农业大学 | 一种抗氧化与抗衰老双效益生菌及其应用 |
CN116716203B (zh) * | 2022-11-28 | 2024-02-02 | 朗恒科技集团有限公司 | 一株具有高抗氧化性的植物乳杆菌sc75-2-2及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101144065A (zh) * | 2007-09-03 | 2008-03-19 | 江南大学 | 一种耐过氧化氢、清除自由基的抗氧化干酪乳杆菌及其用途 |
CN101333505A (zh) * | 2007-06-26 | 2008-12-31 | 内蒙古农业大学 | 一种干酪乳杆菌在抗氧化作用方面的应用 |
KR101239806B1 (ko) * | 2011-04-01 | 2013-03-06 | 주식회사한국야쿠르트 | 면역증강 활성을 가지는 신규한 락토바실러스 플란타룸 에이취와이 7712 |
JP2013048586A (ja) * | 2011-08-31 | 2013-03-14 | Ishikawa Prefectural Public Univ Corp | 石川県の伝統発酵食品から分離した乳酸菌、その培養物及びその利用 |
CN104781390A (zh) * | 2012-08-16 | 2015-07-15 | 庆熙大学校产学协力团 | 具有对衰老及痴呆的预防和/或治疗活性的乳酸菌 |
CN105018379A (zh) * | 2015-07-16 | 2015-11-04 | 山东凤凰生物有限公司 | 一株具高抗氧化活性的植物乳杆菌及其应用 |
CN105132318A (zh) * | 2015-09-01 | 2015-12-09 | 扬州大学 | 植物乳杆菌Grx16及其应用 |
CN105969681A (zh) * | 2016-03-28 | 2016-09-28 | 四川农业大学 | 一株高抗氧化耐胆盐耐酸植物乳杆菌jr4及其应用 |
-
2018
- 2018-08-17 CN CN201810941395.3A patent/CN109182162B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101333505A (zh) * | 2007-06-26 | 2008-12-31 | 内蒙古农业大学 | 一种干酪乳杆菌在抗氧化作用方面的应用 |
CN101144065A (zh) * | 2007-09-03 | 2008-03-19 | 江南大学 | 一种耐过氧化氢、清除自由基的抗氧化干酪乳杆菌及其用途 |
KR101239806B1 (ko) * | 2011-04-01 | 2013-03-06 | 주식회사한국야쿠르트 | 면역증강 활성을 가지는 신규한 락토바실러스 플란타룸 에이취와이 7712 |
JP2013048586A (ja) * | 2011-08-31 | 2013-03-14 | Ishikawa Prefectural Public Univ Corp | 石川県の伝統発酵食品から分離した乳酸菌、その培養物及びその利用 |
CN104781390A (zh) * | 2012-08-16 | 2015-07-15 | 庆熙大学校产学协力团 | 具有对衰老及痴呆的预防和/或治疗活性的乳酸菌 |
CN105018379A (zh) * | 2015-07-16 | 2015-11-04 | 山东凤凰生物有限公司 | 一株具高抗氧化活性的植物乳杆菌及其应用 |
CN105132318A (zh) * | 2015-09-01 | 2015-12-09 | 扬州大学 | 植物乳杆菌Grx16及其应用 |
CN105969681A (zh) * | 2016-03-28 | 2016-09-28 | 四川农业大学 | 一株高抗氧化耐胆盐耐酸植物乳杆菌jr4及其应用 |
Non-Patent Citations (1)
Title |
---|
青藏高原高抗氧化活性乳酸菌的筛选及其抗氧化特性研究;陈明;《中国优秀硕士学位论文全文数据库 基础科学辑》;20170815;摘要,第1-40页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109182162A (zh) | 2019-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109182162B (zh) | 一株具有抗氧化能力的植物乳杆菌及应用 | |
de Melo Pereira et al. | How to select a probiotic? A review and update of methods and criteria | |
CN111235070B (zh) | 一株母乳婴儿源植物乳杆菌bf_15及其应用 | |
Nami et al. | Hypocholesterolaemic activity of a novel autochthonous potential probiotic Lactobacillus plantarum YS5 isolated from yogurt | |
Ding et al. | Characterization of antioxidant properties of lactic acid bacteria isolated from spontaneously fermented yak milk in the Tibetan Plateau | |
CN109234189A (zh) | 一株具有抗氧化能力的植物乳杆菌菌株bx62及其应用 | |
CN110684697B (zh) | 一种具有抗氧化功能的发酵乳杆菌jx306及其用途 | |
US20160074442A1 (en) | Method of making a medication or a food supplement | |
CN114672443A (zh) | 一株具有预防或改善面部泛红和i型玫瑰痤疮功能的植物乳植杆菌 | |
Rezaei et al. | Isolation of lactic acid probiotic strains from Iranian camel milk: technological and antioxidant properties | |
Zhou et al. | Probiotic assessment and antioxidant characterization of Lactobacillus plantarum GXL94 isolated from fermented chili | |
CN106544287A (zh) | 一株具有抗氧化能力及产细菌素的德式乳杆菌 | |
CN109983115B (zh) | 一种加氏乳杆菌及其培养方法和应用 | |
Kesen et al. | Beneficial characteristics and evaluation criteria of probiotics | |
CN114752529A (zh) | 植物乳杆菌hom3201菌株及其活菌制剂、制备方法和用途 | |
CN114642686A (zh) | 一种复合益生菌及其延缓衰老和抗氧化的作用 | |
CN112080449B (zh) | 一种屎肠球菌r40及其在降胆固醇、产胞外多糖和抗氧化中的应用 | |
Rubbani et al. | Evaluation of isolated Lactobacillus strains as Probiotics in yogurt preparation | |
CN113337440A (zh) | 一株唾液乳杆菌mg-587及其应用 | |
CN116987644A (zh) | 一株具有抗氧化作用的发酵粘液乳杆菌及应用 | |
CN116769655A (zh) | 一种唾液链球菌嗜热亚种jian+及其应用 | |
CN116606781A (zh) | 一株具有拮抗幽门螺旋杆菌能力的植物乳植杆菌及其应用 | |
CN113913334B (zh) | 一株粪肠球菌ef-za1107-06及其应用 | |
Xu et al. | Probiotic characterization and comparison of broiler-derived lactobacillus strains based on technique for order preference by similarity to ideal solution analysis | |
Rahman et al. | Probiotic Potentiality of Lactobacillus coryniformis subsp. Torquens MTi1 and Lactobacillus coryniformis MTi2 Isolated from Intestine of Nile Tilapia: An In vitro Evaluation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200131 Address after: 150000 Airport Road, Daoli District, Harbin City, Heilongjiang Province, 22km Applicant after: Harbin Meihua Biotechnology Co., Ltd. Address before: Room 1405, Industrial Incubation Building, Lanzhou New District, Lanzhou City, Gansu Province Applicant before: Gansu Punobokang Biotechnology Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |